Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Spinal Muscular Atrophy Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

80 recruiting trials for Spinal Muscular Atrophy. Eligibility criteria explained in plain English.

TrialFinderData lists 80 Spinal Muscular Atrophy clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 3 is the largest group at 29% (6 studies); the largest phase groups are Phase 3: 6, Phase 1 / Phase 2: 6, Phase 2: 5, Phase 4: 2.

Research is led by Novartis Pharmaceuticals (4), Biogen (4), GeneCradle Inc (3), among the most active sponsors registered for these trials.

The most frequently studied intervention is Risdiplam (drug, 4 trials), followed by Placebo, blood sample.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
80
Total Trials
80
Recruiting Now
6
Phase 3 Trials
10
Sponsors

Track Spinal Muscular Atrophy trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT07478172

Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease

This single-arm pilot study evaluates the effects of whole-body electrical muscle stimulation (WB-EMS) exercise on neuromuscular and physical function in adults with neuromuscular...

Sponsor: University of Missouri-ColumbiaEnrolling: 501 location
RECRUITINGNCT05663008

Impairments of Neuro-muscular Communication in Motor-Neuron Disease: A Bio-Marker for Early and Personalised Diagnosis

Motor neuron disease (MND) or ALS is a nervous system disease. ALS leads to a loss of movement ability that eventually leads to death. At the moment, there is no known treatment...

Sponsor: University of Dublin, Trinity CollegeEnrolling: 4001 location
RECRUITINGNCT06756633

Respiratory Functions, Thoracoabdominal Movements and Exercise Capacity in Neuromuscular Diseases

The clinical trial titled "Investigation of Respiratory Functions, Thoracoabdominal Movements, and Exercise Capacity in Neuromuscular Diseases" aims to evaluate the respiratory...

Sponsor: Lokman Hekim UniversityEnrolling: 421 location
RECRUITINGNCT06539169

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases. Patients participate in...

Sponsor: xCuresEnrolling: 10001 location
RECRUITINGNCT07332702

Long Read Analysis in Spinal Muscular Atrophy - LOREASI

Spinal Muscular Atrophy (SMA) is a severe neuromuscular disease caused by deletion of the SMN1 gene, with the most severe form leading to death in children without treatment....

Sponsor: University Hospital, RouenEnrolling: 271 location
RECRUITINGNCT05341453

Hippotherapy in Children With Spinal Muscular Atrophy

The randomized controlled trial is aimed to discover the physiotherapy and hippotherapy effect and efficacy on children with SMA. The concept is to utilized two types of...

Sponsor: Charles University, Czech RepublicEnrolling: 161 location
RECRUITINGNCT06019637

A Long-term Safety Study in Brazilian Patients With a Diagnosis of Spinal Muscular Atrophy Treated With Zolgensma

A long-term safety study in Brazilian patients with a confirmed diagnosis of Spinal Muscular Atrophy (SMA) treated with Onasemnogene Abeparvovec (Zolgensma®)

Sponsor: Novartis PharmaceuticalsEnrolling: 502 locations
RECRUITINGPhase 2NCT07047144

A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy

This double-blind, Phase 2, multiple-dose study will be conducted to evaluate the PK/PD, efficacy, safety, and tolerability of apitegromab in subjects \<2 years old with 5q...

Sponsor: Scholar Rock, Inc.Enrolling: 5220 locations
RECRUITINGNCT06689618

Effects of Whole-body Electrical Muscle Stimulation Exercise on Spinal Motoneuronal Activation in Older Adults

During this pilot study, the investigators will examine the effects of whole-body electrical muscle stimulation exercise (WB-EMS Exercise) on motoneuronal activation in healthy...

Sponsor: University of Missouri-ColumbiaEnrolling: 121 location
RECRUITINGNCT07578454

VRehab-SMA Phase 1.2

Spinal muscular atrophy is a genetic disorder characterized by progressive muscle weakness, severely impacting patients' motor abilities. Several disease modifying therapies have...

Sponsor: University of OxfordEnrolling: 121 location
RECRUITINGNCT04174157

Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN...

Sponsor: Novartis PharmaceuticalsEnrolling: 70020 locations
RECRUITINGPhase 3NCT06971094

Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With...

This trial employs a multicenter, randomized, open-label, standard-of-care-controlled design and plans to enroll 50 patients with Type 2 SMA aged 2 to 12 years who have previously...

Sponsor: GeneCradle IncEnrolling: 507 locations
RECRUITINGNCT05755451

Natural History of SMA

This is an investigator initiated observational study with the aim to record several aspects of function, care and adverse events in a large cohort of SMA patients followed...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 12005 locations
RECRUITINGNCT07286565

Active NBS Study: Decentralised Monitoring Motor Development in Children With Duchenne Muscular Dystrophy or Spinal...

The Active NBS Liege study is a monocentric, academic, fully remote, observational study designed to validate digital measures of motor development in children with spinal...

Sponsor: Centre Hospitalier Universitaire de LiegeEnrolling: 1001 location
RECRUITINGNCT04944940

Clinical, Molecular and Imaging Biomarkers in Spinal and Bulbar Muscular Atrophy (SBMA)

Background: SBMA is an inherited chronic disease. It affects males in mid to late adulthood. It causes slowly progressive weakness of muscles and hand tremors. Researchers want...

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)Enrolling: 701 location
RECRUITINGPhase 2NCT06365788

Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer

This study has as goal to evaluate the use of abemaciclib and bicalutamide in androgen receptor positive metastatic triple negative breast cancer.

Sponsor: Universitaire Ziekenhuizen KU LeuvenEnrolling: 536 locations
RECRUITINGPhase 1 / Phase 2NCT05824169

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients

The study will evaluate safety and efficacy of intrathecal delivery of GC101 gene therapy drug as a treatment of spinal muscular atrophy Type 1 (SMA 1) patients.

Sponsor: GeneCradle IncEnrolling: 184 locations
RECRUITINGPhase 2NCT06169046

A Placebo-controlled Study of Clenbuterol in Spinal and Bulbar Muscular Atrophy

There is no cure to arrest or delay SBMA progression. It is estimated that \~1000 individuals are affected by SBMA in Italy at any given time (prevalence: 1.5/100000) with an...

Sponsor: Gianni SoraruEnrolling: 901 location
RECRUITINGNCT07231549

CuidAME: Longitudinal Data Collection From Patients With Spinal Muscular Atrophy in Spain

The goal of this observational study is to set up a longitudinal data collection study to perform a long-term follow-up of SMA patients in a real-world setting, and to standardise...

Sponsor: Fundació Sant Joan de DéuEnrolling: 10001 location
RECRUITINGNCT05204017

Comprehensive Analysis Platform To Understand, Remedy and Eliminate ALS

CAPTURE ALS is a long-term data and biorepository platform that will facilitate future ALS research. CAPTURE ALS will provide the standardized systems and tools necessary to...

Sponsor: University of AlbertaEnrolling: 1504 locations
RECRUITINGNCT01793168

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international...

Sponsor: Sanford HealthEnrolling: 200002 locations
RECRUITINGPhase 2NCT06290713

Vasodilator and Exercise Study for DMD (VASO-REx)

Examining two strategies as potential adjuvant therapies for Duchenne muscular dystrophy (DMD); aerobic exercise training (to induce adaptations in skeletal muscle and improve...

Sponsor: University of FloridaEnrolling: 501 location
RECRUITINGNCT04708431

Androgen Receptor, Implications for Health and Wellbeing: Natural History Study of Individuals With Androgen...

Background: Androgen effects in humans are usually (but not always) mediated by the androgen receptor which is coded for by the androgen receptor gene (AR gene). Androgen...

Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Enrolling: 6501 location
RECRUITINGNCT05966038

ALS/MND Natural History Study Data Repository

This is a data repository for multi-site multi-protocol clinic-based Natural History Study of ALS and Other Motor Neuron Disorders (MND). All people living with ALS or other MNDs...

Sponsor: Massachusetts General HospitalEnrolling: 500018 locations
RECRUITINGPhase 1 / Phase 2NCT06421831

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients

The study will evaluate safety and efficacy of intrathecal delivery of GC101 gene therapy drug as a treatment of spinal muscular atrophy Type 3 (SMA 3) patients.

Sponsor: GeneCradle IncEnrolling: 211 location
RECRUITINGNCT04010604

A Registered Cohort Study on SMA

Spinal muscular atrophy (SMA) is an autosomal recessive disease that causes progressive muscle wasting and weakness due to loss of motor neurons in the spinal cord. This is a...

Sponsor: Wan-Jin ChenEnrolling: 20001 location
RECRUITINGNCT06321965

Characterization of New Phenotypes of Patients With Spinal Muscular Atrophy Treated With SMN Restoring Therapy

With the advent of new treatments for ASI, new phenotypes are emerging. The investigators propose to describe these new phenotypes by prospectively following children with ASI of...

Sponsor: Hospices Civils de LyonEnrolling: 608 locations
RECRUITINGNCT07321977

Assessment of a Portable Digital Device for Quantified Analysis of Markerless Walking in Volunteers With Neuromuscular...

In recent years, knowledge of neuromuscular diseases has advanced considerably, and new therapeutic avenues are beginning to emerge. The proliferation of clinical trials has...

Sponsor: Institut de Myologie, FranceEnrolling: 301 location
RECRUITINGNCT05724173

Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia

The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control...

Sponsor: Leigh R. Hochberg, MD, PhD.Enrolling: 32 locations
RECRUITINGNCT03489278

Clinical Procedures to Support Research in ALS

The purpose of the Clinical Procedures To Support Research (CAPTURE) study is to utilize information collected in the medical record to learn more about a disease called...

Sponsor: University of MiamiEnrolling: 120011 locations
RECRUITINGNCT03698149

ECoG BMI for Motor and Speech Control

Test the feasibility of using electrocorticography (ECoG) signals to control complex devices for motor and speech control in adults severely affected by neurological disorders.

Sponsor: Karunesh GangulyEnrolling: 31 location
RECRUITINGNCT06147414

Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders

Cell-free fetal DNA (cffDNA) is present in the maternal blood from the early first trimester of gestation and makes up 5%-20% of the total circulating cell-free DNA (cfDNA) in...

Sponsor: Assistance Publique - Hôpitaux de ParisEnrolling: 5501 location
RECRUITINGNCT03940911

Fatigue and Skeletal Muscle Impact in Severe Axial Spondyloarthritis

Axial spondyloarthropathy (SpA) is the most common inflammatory rheumatism (1% of the general population) with important medico-economic consequences. Fatigue is a major feature...

Sponsor: University Hospital, Strasbourg, FranceEnrolling: 1221 location
RECRUITINGNCT07223489

Diagnostic Journey, Patient Experience, and Disparities in the Treatment of Spinal Muscular Atrophy (SMA) in the...

Evaluate the diagnostic journey, patient experience, and disparities in the treatment of Spinal Muscular Atrophy (SMA) in the MedStar Health System.

Sponsor: Medstar Health Research InstituteEnrolling: 2001 location
RECRUITINGNCT07488338

HABIT-ILE + FST in Children With SMA: Preliminary Effectiveness

This single-arm pilot study will assess the preliminary effectiveness of an intensive motor skill intervention (HABIT-ILE) combined with functional strength training (FST) in...

Sponsor: Teachers College, Columbia UniversityEnrolling: 201 location
RECRUITINGPhase 1 / Phase 2NCT07336446

A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or...

ANDROMEDA is a first-in-human, Phase I/II, open-label, multicenter study of AZD9750 in participants with metastatic prostate cancer. The trial evaluates safety, tolerability,...

Sponsor: AstraZenecaEnrolling: 30018 locations
RECRUITINGPhase 3NCT06764485

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants...

The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant...

Sponsor: CelgeneEnrolling: 96020 locations
RECRUITINGNCT05768048

Long Term Trajectories of SMA Patients Receiving or Not Disease-modifying Treatments

This is an observational multicenter retrospective and prospective study on natural history of SMA also considering the 'new natural history' secondary to the availability of...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 5005 locations
RECRUITINGNCT00912041

BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia

The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control...

Sponsor: Leigh R. Hochberg, MD, PhD.Enrolling: 276 locations
RECRUITINGNCT07543003

An International Federated Model for Wearable-derived Remote Longitudinal Motor Monitoring in Young Children With...

Active-NBS is a study to evaluate the muscle development of patients with spinal muscular atrophy (SMA) who are diagnosed at birth. Medicines have become available in the last...

Sponsor: University of OxfordEnrolling: 901 location
RECRUITINGPhase 2 / Phase 3NCT06862596

Clinical Trial of Mexiletine Hydrochloride for Spinal and Bulbar Muscular Atrophy

The purpose of this clinical trial is to evaluate the efficacy and safety of mexiletine hydrochloride in patients with spinal and bulbar muscular atrophy. The main questions it...

Sponsor: Masahisa KatsunoEnrolling: 685 locations
RECRUITINGNCT06194539

Assessing the Fertility Status of Men With Spinal Muscular Atrophy (SMA)

This study will aim to assess the fertility status of men with Spinal Muscular Atrophy (SMA) not on disease-modifying therapies. Participants will: 1. Complete online...

Sponsor: Bar-Chama, Natan, M.D.Enrolling: 751 location
RECRUITINGNCT06094205

Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02)

The goal of this study is to improve our understanding of speech production, and to translate this into medical devices called intracortical brain-computer interfaces (iBCIs) that...

Sponsor: Leigh R. Hochberg, MD, PhD.Enrolling: 21 location
RECRUITINGNCT06955897

Characterizing Perceived Physical Fatigability in Nusinersen-treated SMA

The purpose of this project is to investigate the utility of the SMA EFFORT, an SMA-specific patient-reported outcome measure, to assess perceived physical fatigability that is...

Sponsor: Columbia UniversityEnrolling: 451 location
RECRUITINGNCT06363357

The Effect of a Muscle-mimicking, Fabric-type Shoulder Orthosis on Functional Movements of the Upper Limb in Patients...

The goal of this clinical trial is to investigate the effect of a muscle-mimicking, fabric-type shoulder orthosis on functional movements of the upper limb in patients with...

Sponsor: Seoul National University HospitalEnrolling: 301 location
RECRUITINGNCT07521930

Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)

The goal of this clinical trial is to evaluate the safety and preliminary efficacy of an implantable device that records and stimulates different areas of the brain to allow...

Sponsor: Johns Hopkins UniversityEnrolling: 51 location
RECRUITINGPhase 1 / Phase 2NCT07070999

Study of Safety, Tolerability and Efficacy of GB221 in Infants With Spinal Muscular Atrophy Type 1

GB221 is a gene therapy that delivers a working SMN1 gene to the motor neurons of people with spinal muscular atrophy (SMA) Type 1. This study will evaluate the safety,...

Sponsor: Gemma BiotherapeuticsEnrolling: 221 location
RECRUITINGNCT06978985

Adult SMA Research and Clinical Hub

Adult SMA REACH is a data collection study aiming to gain a better understanding of the impact of standards of care and new treatments on the natural history of Spinal Muscular...

Sponsor: Newcastle-upon-Tyne Hospitals NHS TrustEnrolling: 60018 locations
RECRUITINGNCT03217578

Neonatal Spinal Muscular Atrophy (SMA) Screening

Parents or legal guardian of neonates who signed agreement will receive SMA screening test if their neonates are affected with SMA. The dried blood spots of routine newborn...

Sponsor: Kaohsiung Medical University Chung-Ho Memorial HospitalEnrolling: 2500001 location
RECRUITINGPhase 3NCT07265232

Real World Clinical Effectiveness & Safety of Vesemnogene Lantuparvovec for Spinal Muscular Atrophy (SMA) in Low-middle...

The study objective is to determine the real-world safety and effectiveness of Vesemnogene lantuparvovec for the treatment of SMA. The specific objectives are: * To determine...

Sponsor: Lantu BiopharmaEnrolling: 151 location

Showing 50 of 80 trials.Search all Spinal Muscular Atrophy trials

Frequently Asked Questions

There are currently 80 clinical trials for Spinal Muscular Atrophy, with 80 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Spinal Muscular Atrophy, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 6 Phase 3 trials for Spinal Muscular Atrophy, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.